{"id":6680,"date":"2024-11-21T16:01:26","date_gmt":"2024-11-21T15:01:26","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6680"},"modified":"2025-04-28T22:03:58","modified_gmt":"2025-04-28T20:03:58","slug":"patient-reported-outcomes-in-patients-with-relapsed-or-refractory-follicular-lymphoma-treated-with-zanubrutinib-plus-obinutuzumab-versus-obinutuzumab-monotherapy-results-from-the-rosewood-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/patient-reported-outcomes-in-patients-with-relapsed-or-refractory-follicular-lymphoma-treated-with-zanubrutinib-plus-obinutuzumab-versus-obinutuzumab-monotherapy-results-from-the-rosewood-trial\/","title":{"rendered":"Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6680","publication","type-publication","status-publish","hentry","disease_state-follicular-lymphoma","molecule-zanubrutinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6680"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}